Mylan Has Green Light On Remdesivir
Follows Cipla And Hetero Launches Of COVID-19 Treatment
Lauding a “significant milestone for Mylan, for the global public health community and, most importantly, for patients who are battling this pandemic,” Mylan has received approval in India for its remdesivir 100mg/vial product licensed from Gilead Sciences.
You may also be interested in...
Mylan has seen its second-quarter performance echo that of its industry peers, with a lift provided by COVID-19 related demand in the first three months of the year balanced out by declines in the second quarter of 2020.
Mylan says it is closing in on $1bn in cumulative sales of its biosimilars, also disclosing its annual turnover figure from biosimilars as it reported its second-quarter results.
The WHO’s “Solidarity” trial investigators have decided to interrupt the trials with immediate effect since the clinical trial found that hydroxychloroquine and lopinavir/ritonavir “produced little or no reduction in the mortality of the hospitalized COVID-19 patients.”